Switch theme
Sign up to access all valuation multiples
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
2018
1.1K+
LTM Revenue $251M
LTM EBITDA $80.8M
$4.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cohance Lifesciences has a last 12-month revenue (LTM) of $251M and a last 12-month EBITDA of $80.8M.
In the most recent fiscal year, Cohance Lifesciences achieved revenue of $140M and an EBITDA of $50.8M.
Cohance Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cohance Lifesciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $251M | XXX | $140M | XXX | XXX | XXX |
| Gross Profit | $147M | XXX | $104M | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $80.8M | XXX | $50.8M | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 36% | XXX | XXX | XXX |
| EBIT | $68.3M | XXX | $34.9M | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $53.9M | XXX | $31.0M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cohance Lifesciences's stock price is INR 1045 (or $12).
Cohance Lifesciences has current market cap of INR 400B (or $4.7B), and EV of INR 400B (or $4.7B).
See Cohance Lifesciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.7B | $4.7B | XXX | XXX | XXX | XXX | $0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cohance Lifesciences has market cap of $4.7B and EV of $4.7B.
Cohance Lifesciences's trades at 34.5x EV/Revenue multiple, and 90.4x EV/EBITDA.
Equity research analysts estimate Cohance Lifesciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cohance Lifesciences has a P/E ratio of 86.9x.
See valuation multiples for Cohance Lifesciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.7B | XXX | $4.7B | XXX | XXX | XXX |
| EV (current) | $4.7B | XXX | $4.7B | XXX | XXX | XXX |
| EV/Revenue | 18.6x | XXX | 34.5x | XXX | XXX | XXX |
| EV/EBITDA | 57.9x | XXX | 90.4x | XXX | XXX | XXX |
| EV/EBIT | 68.5x | XXX | 128.1x | XXX | XXX | XXX |
| EV/Gross Profit | 31.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 86.9x | XXX | 146.1x | XXX | XXX | XXX |
| EV/FCF | 429.9x | XXX | 227.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCohance Lifesciences's last 12 month revenue growth is 61%
Cohance Lifesciences's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Cohance Lifesciences's rule of 40 is 100% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cohance Lifesciences's rule of X is 185% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cohance Lifesciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 61% | XXX | 83% | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | 66% | XXX | 74% | XXX | XXX | XXX |
| Rule of 40 | 100% | XXX | 100% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 185% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 50% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cohance Lifesciences acquired XXX companies to date.
Last acquisition by Cohance Lifesciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Cohance Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cohance Lifesciences founded? | Cohance Lifesciences was founded in 2018. |
| Where is Cohance Lifesciences headquartered? | Cohance Lifesciences is headquartered in India. |
| How many employees does Cohance Lifesciences have? | As of today, Cohance Lifesciences has 1.1K+ employees. |
| Is Cohance Lifesciences publicy listed? | Yes, Cohance Lifesciences is a public company listed on BOM. |
| What is the stock symbol of Cohance Lifesciences? | Cohance Lifesciences trades under 543064 ticker. |
| When did Cohance Lifesciences go public? | Cohance Lifesciences went public in 2020. |
| Who are competitors of Cohance Lifesciences? | Similar companies to Cohance Lifesciences include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Cohance Lifesciences? | Cohance Lifesciences's current market cap is $4.7B |
| What is the current revenue of Cohance Lifesciences? | Cohance Lifesciences's last 12 months revenue is $251M. |
| What is the current revenue growth of Cohance Lifesciences? | Cohance Lifesciences revenue growth (NTM/LTM) is 61%. |
| What is the current EV/Revenue multiple of Cohance Lifesciences? | Current revenue multiple of Cohance Lifesciences is 18.6x. |
| Is Cohance Lifesciences profitable? | Yes, Cohance Lifesciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cohance Lifesciences? | Cohance Lifesciences's last 12 months EBITDA is $80.8M. |
| What is Cohance Lifesciences's EBITDA margin? | Cohance Lifesciences's last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of Cohance Lifesciences? | Current EBITDA multiple of Cohance Lifesciences is 57.9x. |
| What is the current FCF of Cohance Lifesciences? | Cohance Lifesciences's last 12 months FCF is $10.9M. |
| What is Cohance Lifesciences's FCF margin? | Cohance Lifesciences's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Cohance Lifesciences? | Current FCF multiple of Cohance Lifesciences is 429.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
